Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning

Annals of Surgery

Volumn 253, Issue 3, 2011, Pages 572-579

  Yi, Min ^a   Buchholz, Thomas A ^a   Meric Bernstam, Funda ^a   Bedrosian, Isabelle ^a   Hwang, Rosa F ^a   Ross, Merrick I ^a   Kuerer, Henry M ^a   Luo, Sheng ^a   Gonzalez Angulo, Ana M ^a   Buzdar, Aman U ^a   Symmans, W Fraser ^b   Feig, Barry W ^a   Lucci, Anthony ^a   Huang, Eugene H ^c   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c North Coast Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BAYES THEOREM; BREAST CANCER; BREAST CARCINOMA; BREAST CONSERVATION THERAPY; BREAST SURGERY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; METASTASIS; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATIENT CARE PLANNING; PROGNOSIS; REOPERATION; TUMOR MARKERS, BIOLOGICAL;

EID: 79951675741     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318208fc2a     Document Type: Article

References (42)

1. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoad-juvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004;22(12):2303-2312 (Pubitemid 41115386)
2. Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19(4):833-842 (Pubitemid 20345149)
3. Rouzier R, Extra JM, Carton M, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001;19(18): 3828-3835 (Pubitemid 32880061)
4. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-1150
5. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338(8763):327-331
6. Haffty BG, Fischer D, Beinfield M, et al. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21(2):293-298
7. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 1989;63(10):1912-1917 (Pubitemid 19118888)
8. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol. 2009;27(15):2466-2473
9. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-2037 (Pubitemid 46622111)
10. Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995;87(1):19-27
11. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002;95:2059-2067 (Pubitemid 35253366)
12. Abd-Alla HM, Lotayef MM, Abou Bakr A, et al. Ipsilateral in-breast tumor relapse after breast conservation therapy: true recurrence versus new primary tumor. J Egypt Natl Canc Inst. 2006;18(3):183-190
13. Nimeus-MalmstromE,KroghM,MalmstromP,etal. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res. 2008;10(2):R34
14. Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281-1289
15. Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004;22:1830-1838 (Pubitemid 41095173)
16. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclas-sification in the estimation of relative risk. Am J Epidemiol. 1977;105(5): 488-495 (Pubitemid 8112070)
17. Johnson WO, Gastwirth JL. Bayesian Inference for medical screening tests: approximations useful for the analysis of acquired immune deficiency syndrome. J Royal Stat Soc, SerB: Methodol. 1991;53:427-439
18. Mendoza-Blanco JR, Tu XM, Iyengar S. Bayesian inference on prevalence using a missing-data approach with simulation-based techniques: applications to HIV screening. Stat Med. 1996;15:2161-2176 (Pubitemid 26394650)
19. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-76 (Pubitemid 8308186)
20. Tu XM, Litvak E, Pagano M. Issues in HIV screening programs. Am J Epidemiol. 1992;136:244-255
21. Tu XM, Litvak E, Pagano M. On the informativeness and accuracy of pooled testing in estimating prevalence of a rare disease: application to HIV screening. Biometrika. 1995;82:287-297
22. Magder LS, Hughes JP. Logistic regression when the outcome is measured with uncertainty. Am J Epidemiol. 1997;146(2):195-203
23. Tu XM, Kowalski J, Jia G. Bayesian analysis of prevalence with covariates using simulation-based techniques: applications to HIV Screening. Stat Med. 1999;18:3059-3073 (Pubitemid 29526944)
24. McInturff P, Johnson WO, Cowling D, et al. Modelling risk when binary outcomes are subject to error. Stat Med. 2004;23(7):1095-1109 (Pubitemid 38477069)
25. Paulino CD, Soares P, Neuhaus J. Binomial regression with misclassification. Biometrics. 2003;59(3):670-675 (Pubitemid 37093406)
26. Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52-57 (Pubitemid 26019996)
27. Recht A, Silen W, Schnitt SJ, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15(2):255-261
28. Komoike Y, Akiyama F, Iino Y, et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005;12:104-111
29. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71(9):711-714 (Pubitemid 14066682)
30. Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys. 1993;27:575-583 (Pubitemid 23331124)
31. Iglehart JD, Kerns BJ, Huper G, et al. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat. 1995;34(3):253-263
32. Lacroix H, Iglehart JD, Skinner MA, et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 1989;4(2):145-151 (Pubitemid 19096937)
33. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14(9):2584-2589 (Pubitemid 26300127)
34. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985;12(3):317-326 (Pubitemid 16214558)
35. Shimizu C, Fukutomi T, Tsuda H, et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol. 2000;73(1):17-20 (Pubitemid 30067528)
36. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of her2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Can Res. 2009;15(23):7381-7388
37. Akcakanat A, Sahin A, Shaye AN, et al. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008;112(11):2352-2358
38. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953-1958
39. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25
40. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-2826 (Pubitemid 40051905)
41. Mamounas E, Tang G, Bryant J, et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat. 2005;94(suppl.1):S16
42. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27(28):4701-4708